Janssen Biotech, Inc. manufactures Balversa.
Understanding Balversa and Its Manufacturer
Balversa, a specialized medication, is developed and produced by Janssen Biotech, Inc., a pharmaceutical company based in Horsham, PA. This medication represents an important advancement in targeted cancer therapy, offering a specific treatment option for certain patients.
About Janssen Biotech, Inc.
Janssen Biotech, Inc. is a well-known name in the biopharmaceutical industry, focusing on developing innovative solutions for complex diseases. As part of the Janssen Pharmaceutical Companies of Johnson & Johnson, it is dedicated to research and development in various therapeutic areas, including oncology, immunology, neuroscience, infectious diseases, and cardiovascular and metabolic diseases. Their commitment lies in bringing transformative medicines to patients in need.
What is Balversa?
Balversa (active ingredient: erdafitinib) is a prescription medication categorized as a kinase inhibitor. It is specifically indicated for the treatment of adult patients diagnosed with locally advanced or metastatic urothelial carcinoma (mUC). This particular therapy is crucial for patients whose disease carries susceptible FGFR3 genetic alterations and has progressed following at least one prior line of systemic therapy.
Key facts about Balversa:
- Active Ingredient: Erdafitinib
- Drug Class: Kinase inhibitor
- Manufacturer: Janssen Biotech, Inc.
- Primary Indication: Treatment of specific forms of urothelial carcinoma (mUC) with FGFR3 genetic alterations.
- Usage Context: For patients whose disease has progressed after prior systemic therapy.
For more detailed information on this medication, healthcare professionals and patients can refer to the official resources provided by the manufacturer. You can find more comprehensive details about its usage, efficacy, and safety profile on its dedicated professional website at www.balversahcp.com.
The Role of Kinase Inhibitors in Cancer Treatment
Kinase inhibitors like Balversa are a type of targeted therapy. They work by blocking the activity of specific enzymes called kinases, which play a critical role in cell growth and division. In certain cancers, these kinases can become overactive or mutated, leading to uncontrolled cell proliferation. By inhibiting these specific kinases (in Balversa's case, those associated with FGFR3), the drug aims to stop or slow the growth of cancer cells, thereby providing a more precise treatment approach compared to traditional chemotherapy. This targeted mechanism reduces harm to healthy cells, potentially leading to a more favorable side effect profile for some patients.
